Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07188558 | A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | PHASE3 | RECRUITING | 400 | — | — | Jan 12, 2026 | Jan 1, 2032 | Jun 8, 2026 | 38 | United States |
The time interval from treatment initiation until the occurrence of a specific event of interest.
| Arm | Type | Description |
|---|---|---|
| Rondecabtagene autoleucel | EXPERIMENTAL | - |
| Investigator's Choice CD19 | ACTIVE_COMPARATOR | axicabtagene ciloleucel, lisocabtagene maraleucel |
| Name | Type | Description |
|---|---|---|
| rondecabtagene autoleucel | BIOLOGICAL | An autologous, dual-targeting CD19/20 CAR T-cell candidate. |
| axicabtagene ciloleucel | BIOLOGICAL | An autologous CD19 CAR T-cell therapy |
| lisocabtagene maraleucel | BIOLOGICAL | An autologous CD19 CAR T-cell therapy |
Key Inclusion Criteria: 1. CAR T cell naïve and eligible to receive a CD19 CART-cell therapy 2. Histologically confirmed large B-cell lymphoma, including the following types defined by (WHO 2022) or International Consensus Classification (2022) * Diffuse large B-cell lymphoma (DLBCL) * Trans...